Nutrients · 9 authors, 8 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The TeLIPro arm received routine care plus scales, step counters, an online portal, blood-glucose self-monitoring equipment, and telemedical coaching; controls received routine care with the same devices except for coaching and glucose monitoring.
The TeLIPro arm received routine care plus scales, step counters, an online portal, blood-glucose self-monitoring equipment, and telemedical coaching; controls received routine care with the same devices except for coaching and glucose monitoring. The primary endpoint after 12 months was the estimated treatment difference (ETD) in HbA1c change overall and HbA1c normalisation in patients with diabetes duration <5 years. The TeLIPro group showed a greater HbA1c reduction (ETD −0.4% [−0.5; −0.2], p < 0.001) after 12 months, with a larger effect in those with diabetes duration ≥5 years (ETD −0.5% [−0.7; −0.3], p < 0.001). The HbA1c normalisation rate in shorter-duration diabetes did not significantly differ (25% vs. 18%). Significant benefits were also reported for body weight, BMI, quality of life, and eating behaviour, though effects were not maintained at the 6-month post-intervention follow-up. Limitations acknowledged in the paper include lower baseline HbA1c and higher systolic blood pressure in some TeLIPro subgroups, differential dropout, and absence of a formula-diet component, which the authors suggest may explain smaller effects than the prior TeLIPro study. Continuous coaching appears necessary to sustain benefits.
